Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||PBRM1 mutant|
|Indication/Tumor Type||clear cell renal cell carcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PBRM1 mutant||clear cell renal cell carcinoma||conflicting||Everolimus||Phase II||Actionable||In a Phase II trial (RECORD-3), PBRM1 mutations were associated with longer first-line progression free survival (12.8 vs 5.5 months) in first-line Afinitor (everolimus)-treated clear cell renal cell carcinoma patients compared to first-line Sutent (sunitinib)-treated patients (PMID: 27751729).||27751729|
|PBRM1 mutant||clear cell renal cell carcinoma||conflicting||Everolimus||Clinical Study - Cohort||Actionable||In a clinical study, PBRM1 truncating mutations were not associated with progression-free survival or overall survival in clear cell renal cell carcinoma patients treated with Afinitor (everolimus) (n=193) (PMID: 31486842).||31486842|
|PubMed Id||Reference Title||Details|
|(27751729)||Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.||Full reference...|
|(31486842)||Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.||Full reference...|